In this observational study, we found that combined basal insulin plus GLP1 RA therapy achieved HbA1C level improvement and weight reductions, diminished glucose fluctuation with safety profiles than premixed insulin regimen among patients of T2D who needed intensification to injectable therapy. The gene discussed is GCG; the disease is type 2 diabetes mellitus.